**3.1 Non-hospitalised patients**

For non-hospitalised patients with COVID-19, antithrombotic therapy or antiplatelet therapy for the prevention of venous thromboembolism (VTE) or arterial thrombosis should not be initiated unless the patient has other indications for therapy (prior PTE or DVT, recent surgery, trauma or immobilisation) or is participating in a clinical trial. Patients with COVID-19 receiving warfarin/acenocoumarol who are isolated and therefore unable to proceed with standardised monitoring of anticoagulation levels may be candidates for switching to direct oral anticoagulation therapy [26].
